Ellen Vitetta is the director of the Cancer Immunobiology Center at the University of Texas Southwestern Medical Center in Dallas.[1][2]
Vitetta is an immunologist who does translational (“bench to bedside”) research.[1] She and her colleagues first described IgD on the surface of murine B cells and she was the co-discoverer of Interleukin-4.[1] Her group demonstrated that IL-4 was a “switch” factor for Ig on B cells. Over the past two decades, she has developed antibody-based “biological missiles” to destroy cancer cells and cells infected with HIV. These novel therapeutics have been evaluated in tissue culture, in animals and, since 1988, in over 300 humans.[1] In 2001, Dr. Vitetta developed a vaccine against ricin, which has been evaluated in the first clinical trial of such a vaccine.
Vitetta is Professor of Microbiology and Immunology, Director of the Cancer Immunobiology Center, and holder of both the Sheryle Simmons Patigian Distinguished Chair in Cancer Immunobiology and a Distinguished Teaching Chair at the University of Texas Southwestern Medical Center in Dallas. She has published close to 500 papers, edited several books, and is a co-inventor on 12 issued patents. She is one of the top 100 most cited biomedical scientists in the world.
Vitetta is a member of the National Academy of Sciences, the American Academy of Arts and Sciences, the Institute of Medicine and the American Academy of Microbiology. She is a founding member R. Franklin Society. She served as president of the American Association of Immunogists in 1994 and received its Mentoring Award in 2002 and its Lifetime Achievement Award in 2007. In 2006, she was elected to the Texas Women's Hall of Fame. She currently serves on the board of advisors of Scientists and Engineers for America, an organization focused on promoting sound science in American government.
Vitetta's former student, Linda Buck, won the Nobel Prize in Physiology or Medicine in 2004.